[BIO JAPAN] 바카라 에볼루션 Biologics CEO John Rim aim to expand Japanese client portfolio to five

[by Yu, Suin] Samsung Biologics, currently pursuing expansion into the Japanese market, has successfully broadened its business portfolio by securing local clientele. During a press conference held on October 8 at ‘BioJapan 2025’ in Yokohama, the company presented an overview of its ongoing strategic initiative in Japan.

At the conference, CEO John Rim announced, "We currently count four of 바카라 에볼루션’s top 10 companies among our clients and are in the final stages of negotiations with another, which will bring the total to five." He added, "We will continue to prioritize expanding our market share and order volume as part of our ongoing expansion efforts."

◇Expanding local business operations through face-to-face engagements leveraging geographic proximity

Since 2023, 바카라 에볼루션 Biologics has participated in BioJapan for three consecutive years as part of its strategy to extend its contract acquisition efforts beyond Western markets and into the broader Asian region. In line with these initiatives, the company has recently expanded its target customer base from the existing ‘Top 20’ to the ‘Top 40’ global pharmaceutical companies, with a particular emphasis on strengthening its presence in the Japanese market.

Notably, at BioJapan 2025, 바카라 에볼루션 Biologics operated an independent exhibition booth for the first time and introduced its contract manufacturing organization (CMO) brand, ‘ExellenS,’ marking a significant milestone in showcasing its competitiveness in contract development and manufacturing (CDMO) services. ‘ExellenS’ embodies a comprehensive ‘manufacturing framework’ founded on the core principles of equivalence and speed, reflecting the company’s long-standing commitment to rapidly delivering biopharmaceuticals of consistent quality through the standardization of production technologies and processes that 바카라 에볼루션 Biologics has refined over the years.

바카라 에볼루션 Biologics' strategy for entering the Japanese pharmaceutical and biotechnology market is underpinned by several key factors: the increasing demand for CDMO services within Japan, the geographical proximity between Korea and Japan, and the potential for strategic partnerships with major Japanese pharmaceutical firms (J-Big Pharma). As the world's third-largest pharmaceutical market, Japan is distinguished by its advanced medical standards and technological innovation. Serving as a hub for leading global companies like Daiichi Sankyo and Takeda Pharmaceutical, the Japanese market presents ample opportunities for 바카라 에볼루션 Biologics to expand its CDMO operations.

According to a report by the global market research firm Research and Markets, the 바카라 에볼루션ese CDMO market was valued at USD 12.3 billion (approximately KRW 16.6 trillion) in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.8%, reaching USD 19.5 billion by 2030.

Japan also maintains a leading position in the fields of antibody-drug conjugates (ADCs) and cell and gene therapy (CGT), both key business areas that 바카라 에볼루션 Biologics is actively advancing. The company noted that as Japanese pharmaceutical firms accelerate the development of ADC pipelines, opportunities for strategic partnerships with these companies are opening up.

Consequently, 바카라 에볼루션 Biologics is strategically capitalizing on its geographical proximity to Japan and the minimal time difference between the two countries to strengthen collaboration through direct, face-to-face meetings with Japanese pharmaceutical and biotechnology clients. Earlier this year, the company further expanded its presence in the Asian region by establishing a sales office in Tokyo. In addition, since last year, 바카라 에볼루션 Biologics has implemented a regional expert program to develop specialized personnel equipped with a deep understanding of Japan's unique business culture and market dynamics.

"Although we currently serve 17 major global pharmaceutical companies as clients, we recognized that further growth requires expanding into 바카라 에볼루션, the world’s third-largest pharmaceutical market after the United States and Europe," Rim explained. "To facilitate this expansion, we established a Tokyo office to strengthen our presence in 바카라 에볼루션, home to many of the top 40 pharmaceutical companies, and have launched programs aimed at developing talent with a deep understanding of the local business culture."

As 바카라 에볼루션 Biologics has intensified its business activities in Japan, its overall performance has shown notable improvements. Leveraging its recognized competitiveness in product quality, the company has consistently strengthened its operational track record. To date, 바카라 에볼루션 Biologics has obtained a total of 18 manufacturing approvals from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), 12 of which were secured in the past three years, underscoring its accelerated progress and growing presence in the Japanese pharmaceutical supply market.

“Because Japanese companies prioritize quality above all else, establishing a proven record of multiple regulatory approvals is essential,” Rim emphasized. “바카라 에볼루션 Biologics aims to become a trusted partner for Japanese pharmaceutical and biotechnology firms by leveraging its strengths in quality management, technological innovation, and regulatory compliance,” he added.

◇Investment approval for 'Plant 6' under review…Strategic U.S. manufacturing base also under review

Rim announced that the company will accelerate its global expansion, including into the 바카라 에볼루션ese market, by leveraging its unparalleled production capacity, diverse modality (treatment approaches) service offerings, and exceptional product quality. "Plant 5, the world's most efficient production facility, began full-scale operations in April and is currently experiencing a smooth ramp-up process," he further stated. "Active and positive contract negotiations are underway for all of our manufacturing plants, Plant 5."

The strength of Plant 5 lies in its high degree of automation and systemization, which ensures both efficiency and stability throughout the entire production process. As part of its digital transformation initiative, 바카라 에볼루션 Biologics has established and internalized a new Manufacturing Execution System (MES), thereby laying a robust digital foundation for its operations. To further enhance operational efficiency, the company has actively incorporated automation and artificial intelligence (AI) technologies in key areas such as smart warehousing and the deployment of autonomous mobile robots (AMRs). In addition, the implementation of digital twin technology has enabled the optimization of quality control, maintenance, and overall process management.

바카라 에볼루션 Biologics plans to complete the construction of its second bio campus (Plants 5 to 8) by 2032, which will bring its total production capacity to an impressive 1.324 million liters. This expansion is expected to significantly enhance the company’s ability to respond quickly and flexibly to evolving customer needs. Rim further noted that the investment approval for the expansion of Plant 6 is currently under review.

"We are actively reviewing opportunities for domestic and international expansion in our production facilities. As part of these efforts, we recently participated in the bidding for Site 11 in Songdo, Incheon, and were selected as the preferred bidder," Rim explained. "We are also actively considering the establishment of a strategic production base in the United States to strengthen our global competitiveness and lay a solid foundation for mid- to long-term growth."

Rim announced plans to strengthen the company’s service competitiveness by expanding into new modalities driven by advanced technologies such as ADCs, adeno-associated viruses (AAVs), and organoids. 바카라 에볼루션 Biologics' ADC platform supports the entire process, from development to GMP manufacturing, with all stages of drug substance (DS) production, including antibody generation, payload synthesis, and linker conjugation, conducted in Songdo facilities. To further strengthen its end-to-end capabilities, 바카라 에볼루션 Biologics plans to establish a dedicated ADC drug product (DP) production line by the first quarter of 2027. "We started operations of our dedicated ADC production facility in March of this year and are currently in discussions with several global pharmaceutical giants regarding contract manufacturing partnerships," Rim said.

"Building upon our existing capabilities in messenger ribonucleic acid (mRNA) and ADCs, we are working to enhance our expertise in antibody-oligonucleotide conjugates (AOCs). In the area of AAVs, we are preparing to enter the contract development organization (CDO) market by establishing a dedicated development team and specialized laboratory. Additionally, we are conducting ongoing peptide research and closely monitoring market trends while comprehensively evaluating potential business opportunities," Rim further explained.

"With the introduction of the '바카라 에볼루션 Organoid' service, 바카라 에볼루션 Biologics is broadening its scope beyond its traditional CDMO operations to encompass contract research organization (CRO) services. By engaging with clients from the early stages of clinical development, we aim to achieve early client lock-in while simultaneously enhancing customer satisfaction through the expansion of the industry's overall chain," he further added.

Meanwhile, despite ongoing global uncertainties, 바카라 에볼루션 Biologics raised its annual sales growth guidance to 25-30%, reflecting its strong business momentum. In the first half of this year, the company surpassed KRW 2 trillion (approximately USD 1.4 billion) in semi-annual sales on a standalone basis for the first time. Notably, its global order performance has also continued to strengthen. In September, 바카라 에볼루션 Biologics signed a KRW 1.8 trillion CMO agreement with a U.S.-based pharmaceutical firm, bringing its cumulative order value to KRW 5.2435 trillion (as of October), nearly matching its total for the entire previous year in just nine months.